Kailera Therapeutics IPO: offering terms from its S-1
Kailera Therapeutics priced its IPO at $16 a share on 17 Apr 2026 and raised $625 million. Its shares trade on Nasdaq as KLRA.
Headlines
- Net loss, 2025
- $149M
- IPO price
- $16
- $625M raised
Kailera Therapeutics IPO terms
From the final prospectus (424B4).
- Exchange
- Nasdaq Global Select Market
- Ticker
- KLRA
- IPO price
- $16
- Shares offered
- 39,062,500
- Raised
- $625M
- Registered
- $613M, the amount the filing fee is paid on
- Underwriters
- J.P. Morgan, Jefferies, Leerink Partners, TD Cowen and Evercore ISI
- First filed
- 27 Mar 2026
Kailera Therapeutics revenue and profit
| Period | Revenue | Operating income | Net income |
|---|---|---|---|
| 2025 | - | -$158M | -$149M |
Kailera Therapeutics share structure and company facts
- Employees
- 145
- Headquarters
- Waltham, Massachusetts
Kailera Therapeutics shares since the IPO
Latest close 26 Oct 2026
- IPO price
- $16
- Priced 17 Apr 2026
- First close
- $26.00
- +63% on the IPO price
- Latest close
- $12.77
- -20% on the IPO price
Kailera Therapeutics' IPO filings
The registration statement, each amendment and the final prospectus, oldest first.
About the data
- Terms and financials are read from Kailera Therapeutics' newest prospectus (424B4 filed 17 Apr 2026) by a Kadoa workflow. Check figures that matter against the filing.
- Registered is the amount the filing fee is paid on, often a placeholder before the price range is set.
- Raised is the IPO price times the shares sold, without the underwriters' option. Trading compares the first and latest close with the IPO price.